More importantly, our combination therapy of CXCL2 overexpression and anti‐PD‐1 reagent also demonstrated powerful therapeutic effects, with much more antitumor neutrophils and CD8+ T cells infiltration to retard HCC progression. The gene discussed is CD8A; the disease is hepatocellular carcinoma.